杨群玉教授经验总结及双石汤合二至丸治疗高血压肾损害的临床及机理研究
|
摘要
第一篇杨群玉教授临床经验、学术思想总结
第一章高血压病中医研究概述
高血压病因病机学说的形成和发展,经历了“上虚则眩”“风、热、痰致眩”、“血瘀致眩”的逐渐完善。近年对其病因病机的研究不断深入,杨群玉教授深受上述先贤古训及同行经验启发,同时结合自身多年临床经验,并在此基础上提出自己对高血压病机的独到见解,认为高血压病机应以肾虚为本,肝阳上亢、血瘀为标,主张以补肾平肝活血治则治疗高血压,在此理论认识指导下,杨教授结合自身临床经验独创经验方“双石汤”。多年临床观察研究表明,该方降压疗效显著。
第二章杨群玉教授临床经验、学术思想总结
1学术思想总结
杨师注重辨证论证,辨病、辨证结合,强调治疗个体化,对于久病顽病尤其注重活血化瘀药物的运用,提倡调畅情志,因病制宜,等,这些学术思想贯穿于其临床治疗的各方面。
2临床经验
杨师对各种内科疾病的治疗用药也因病而异,各有侧重,经验独到,值得继承发扬。
第二篇双石汤合二至丸治疗高血压肾损害的临床及机理研究
高血压病所导致的心、脑、肾等器官损害,是其致残、致死的主要原因。肾脏是高血压相关损害的重要靶器官之一。严重危害人类的健康。高血压肾损害早期,若积极治疗,肾功能是可以逆转的。因此,加强高血压病早期肾损害的研究,是目前一项重要的研究课题。开发作用缓和、持久、平稳降压且具有肾保护作用的药物为当务之急。
第一章相关文献综述
1中医学对高血压肾损害的中医病因病机、治法研究
1.1中医学对高血压肾损害尚无对应的病名。古代医家对其论述甚少,对该病尚缺乏深入、系统的认识,目前中医方面对于高血压病导致早期肾损害的理论及研究报道不多,缺乏系统性理论及防治认识。
1.2高血压肾损害中医治法多样化,有按病机立法治疗、专方治疗、名家经验、综合疗法等,而多种技术和方法的综合运用是其主要的趋势和必然发展方向。
2西医对高血压肾损害的研究进展
高血压肾损害的病因复杂。利用检测尿微量白蛋白等比较敏感的指标早期检测肾损害对该病早期诊治、预防进展有极其重要的作用,其治疗原则主要是重视高血压病的防治,且要求个体化。其防治的最终目的是控制危险因素,保护靶器官,提高患者的生存率。
3双石汤临床研究
杨群玉教授根据临床多年经验,创立了双石汤组方,以滋阴潜阳、熄风活血通络为治疗原则,是治疗高血压病的有效方药。临床研究亦表明该方具有保护血管内皮功能、改善胰岛素抵抗、降低血液流变学指标,调脂等功能,且由于照顾到高血压患者虚实夹杂的实际情况,对中医证候改善疗效更加显著。
4二至丸临床研究
二至丸原载《医方集解》由女贞子、旱莲草按1：1的比例组成,其功能为滋养肝肾。临床上多用其加减治疗各种肾脏疾病。
第二章双石汤合二至丸治疗高血压肾损害的临床及机理研究
在导师的指导下,本研究结合中医基础理论与现代医学知识,根据高血压病早期肾损害的临床特点,提出了高血压病早期肾损害为“肝肾阴虚,阳亢风动,瘀阻肾络”的病机说。以滋补肝肾、平肝熄风、活血通络为治疗大法,拟双石汤合二至丸治疗,同时,在此基础上,进一步研究其与脂联素的关系,以初步探讨其降压保肾的作用机制。
目的：
观察双石汤合二至丸治疗原发性高血压病早期肾损害的疗效及其与脂联素的关系。拟进一步验证其降压及逆转高血压所致肾损害的作用,初步探索其治疗作用的可能机理。
方法：
将60例符合标准的高血压病早期肾损害患者随机分为试验组30例,对照组30例。两组在常规治疗基础上,对照组予洛丁新片治疗,试验组在对照组基础上加用双石汤合二至丸治疗,12周为一疗程,观察治疗前后血压、临床症状、尿微量蛋白、血脂、血液流变学及血清脂联素的变化。
结果：
两组治疗前性别、年龄、体重及体重指数、饮食习惯、病程、并发疾病、血压水平、血压分级、血压危险度分层、中医单项症状等一般资料比较,差异均无显著性意义(P>0.05)。资料分析表明,治疗前两组基线基本一致,具有可比性。
试验组总有效率93.3%；对照组总有效率86.7%,试验组降压疗效优于对照组(P<0.05)。血压变化方面,试验组与对照组均有助于降低血压(P<0.05)；治疗6周后两组间收缩压和舒张压比较,差别无统计学意义(P>0.05)；治疗12周后两组间比较,试验组效果优于对照组(舒张压P<0.05,收缩压P<0.01)。症状变化方面,试验组能显著改善中医症候,疗效优于对照组(P<0.01)。研究同时显示,双石汤合至丸能显著降低尿微量蛋白的排出量(P<0.05～0.01),改善脂代谢(P<0.01),及血液流变学(P<0.05～0.01),试验组疗效明显优于对照组,且用药安全、不良反应少。本研究发现双石汤合二至丸组血清脂联素较对照组显著增高(p<0.05),表明双石汤合二至丸能促进血清脂联素的生成与释放。
结论：
双石汤合二至丸具有平稳、缓和的降压作用,并能逆转高血压病早期肾损害,改善临床症状,其作用是通过多个环节、多个靶点而综合实现的,是治疗高血压病早期肾损害的有效方剂。并且双石汤合二至丸降压保肾作用可能与血清脂联素有关。
本研究继承并发扬导师经验,从理论上深化了中医学对高血压病肾损害的病机的认识,为逆转高血压病早期肾损害提供了新的研究思路和治疗方药,为丰富高血压病的中医治疗做了有益的尝试。同时,首次研究双石汤合二至丸降压保肾作用与脂联素的关系,以初步探讨该方降压保肾的作用机制,具有一定理论意义。
Articlel summary of professor yang qunyu's clinical exper iences and academic thought
Chapter Ⅰ summary of traditional chinese medicine's research into hypertension
The shape and develop of hypertension's etiology and pathogenesis has experienced "the upper shortage leads to dizzy state ","The wind, hot, sputum leads to dizzy state ","Blood stasis leads to dizzy state ", and the theory is perfected gradually. in the recent years. the study of etiology amd pathogenesis of hypentension has been deeply researched constantly. Combining her own clinical experiences with the inspiration of the above ancients'and colleagues'experiences, professor yang qunyu puts forward her own original opinion on pathogenesis of hypentension, which thinks that Xu of the kidney is the fundamental cause of hypertension, liver-yang hyperactivity and blood stasis is its sign, insists that the principle of treating hypertension is to tonify kidney, flat liver, and invigorate the circulation of blood. under the guidance of the theory, professor yang has created her prescription "Shuang Shi Tan " on the basis of her own clinical experiences. the clinical obserservation and research for years shows that the prescription has good effect on lowering blood pressure
Chapter Ⅱ summary of professor yang qunyu's clinical experiences and academic thought
1. summary of professor yang's academic thought
professor yang emphasizes Treatment based on Syndrome differentiation combining disease di fferent iation with Syndrome differentiation and Treatment tailored to the individual. she places emphasis on the use of Chinese medicine for activating blood circulation and eliminating stasis when she cures macronosia. she advocates Widening the sentiment, treating due to illness condition, and so on. these academic thoughts can be seen through out all aspects of her clinical treatment
2. professor yang's linical experiences
professor yang treats medical disease due to illness condition, her original experiences are worth inheriting and promoting
Article Ⅱ The Clinic and Mechanism Study on ShuangShiTangandErZhiWan Prescription in Treating Early Renal Damage in Essential Hypertension
damage of heart, brain and kidney caused by hypertention is the main reason that leads to disablement and death. hypertention threatens the health of human being severely. during the early renal damage in Essential Hypertension, if active efforts are made, the function of kidney can be reversed therefore, it is an important research problem to strengthen the research into the early renal damage at present. and it is urgent to develop renal protection medicine which can lower blood pressure lastingly and smoothly
Ⅰ. reviews of literature
1. Chinese traditional medicine's study on the etiology, pathogenesis and treatment of the renal damage in Essential Hypertension.
(1) In Chinese traditional medicine, renal damage in Essential Hypertension has not a corresponding name, physicians in history had little statement on it, and their record is short of deep and systemic understanding. at present, early renal damage in Essential Hypertension in Chinese traditional medicine theory is seldom reported, let alone systematic treantment and prediction
(2) Treatment on renal damage in Essential Hypertension is varied in Chinese tradional medicine, the comprehensive use of varied technology and methods is the main tendency and invevitable development trend
2. Western medicinel understanding in renal damage in Essential Hypertension
The etiology of renal damage in Essential Hypertension is complex. by testing microalbuminuria and other more sensitive index for the disease, renal damage in Essential Hypertensioncan can be detected and prevented early, The principles of treatment is mainly attached to the prevention and control of hypertension, and require individuation. The ultimate goal is to control the risk, protect target organ, improve patients' surial rates.
3. clinical research into Shuang Shi Tang
based on the clinical experiences, Professor Yang Qunyu created the formula of ShuangShi Tang, which is to increase Ying and Reduce Yang, extinguish the wind, promote the circulation of blood. It is an effective method to cure hypertention. clinical research also shows that the prescription can protect endothelial, improve insulin resistance, reduce hemorheology indices, lipid, and so on. As to the actual situation of patients with hypertension, to TCM syndrome, the prescription's effect is more significant.
4. clinical research of Er Zhi Wan
Er Zhi Wan originally appeared in "Yi Fang Ji Tie". it is make up by fructus ligustri lucidi and Eclipta alba extract according to the ratio of one to one. Its function is to nourish liver and kidney. it is used to treat different kinds of kidney disease in the clinical treatment by adding or substracting to the prescription.
Ⅱ. The Clinic and Mechanism Study on ShuangShiTangandErZhiWan Prescription in Treating Early Renal Damage in Essential Hypertension
Under the guidance of tutor, this study combines the basic theory of TCM and modern medical knowledge with the clinical characteristics of renal damage in Essential Hypertension, concludes that the clinical characteristics of renal damage in Essential Hypertension is that Yin deficiency in liver-kidney, Yang strong and blood stasis in kidney collaterals. with ShuangShiTangandErZhiWan in treatment, which can nourish the patient's liver and kidney, flat liver, extinguish the wind, and promote the circulation of blood to remove collaterals obstruction in the kidney meanwhile, clinical observation is necessary. Based on this, we will Further research the relationship between the prescription and adiponectin. Preliminary discusses the the prescription's mechanism of lowering blood pressure and Protecting kidneys.
Objective
To observe the clinical effect of ShuangShiTangandErZhiWan to treat early renal damage in Essential Hypertension, and the relationship between the prescription and adiponectin.to Probe the effect of the prescription' lowering blood pressure and reversing the renal damage in Essential Hypertension, to Preliminary explore the possible mechanism of the prescription's Therapy effect.
Methods
60patients of Early Renal Damage in Essential HyPertension were divided into two groups at random, they are the treatment group (30cases)and the control group(30cases). Each group is given conventional treatments, the control group is given the BenazeprilHydrochlorideTablets, then the treatment group is added ShuangShiTangandErZhiWan. and12weeks for one period of treatment. the change of blood pressure, the clinical symptoms, the urinary microalbumen excretion, blood lipid, blood rheology and blood adiponectin were observed before and after treatment
Results
there are no significant differences in the two groups's gender, age, body weight and body mass index, dietary habits, course of disease, concurrent disease, blood pressure levels, blood pressure classi f'ication, blood pressure risk stratification and single symptoms before treatment (P>0.05).the information analysis shows that the two group are basically on the same baseline before treatment, their results are comparable.
The total effective rate of the treatment group is93.3%; and the control group is86.7%. the treatment group can lower blood pressure obviously more than the treatment group (p<0.01). as for the blood pressure change, both group can lower blood pressure (P<0.05), and there is no difference between two groups in6weeks, but the treatment group is better than the control group in12weeks (P<0.05~0.01). The study also shows that the prescription can lowerurinary microalbumen excretion significantly (p<0.05^0.01), improve lipid metabolism(p<0.01), Hemorheology (p<0.05-0.01), and improve adiponectin (p<0.05). its efficacy is obvious better than the control group, meanwhile can markedly improve systemic symptom (p<0.01). And the medicine is safe, fewer side effects.
Conclusions
ShuangShiTang and ErZhiWan has smooth, moderate effect on lowering blood pressure, and can reverse early renal damage in Essential Hypertension, improve the clinical symptoms. Its effect come true through multiple links and multiple targets, the medicine is an effective prescription to treat early renal damage in Essential Hypertension. Besides, ShuangShiTang and ErZhiWan's function of lowering blood and protecting kidney may be connected with Serum adiponectin
This study, which inherited and carried forward my tutor's experiences has deepened theoretically the knowledge in TCM pathogenesis of early renal damage in Essential Hypertension, it provides a new kind of research idea and Treatment agent for reversion of early renal damage in Essential Hypertension, and made a beneficial attempt to enrich Chinese medicine treatment. and for the first time, to study the relationship between the prescription and adiponectin. to Preliminary explore the possible mechanism of the prescription's effect on lowering blood pressure and reversing early renal damage in Essential Hypertensionm. so, it has some degree of theoretical significance.
第一章高血压病中医研究概述
高血压病因病机学说的形成和发展,经历了“上虚则眩”“风、热、痰致眩”、“血瘀致眩”的逐渐完善。近年对其病因病机的研究不断深入,杨群玉教授深受上述先贤古训及同行经验启发,同时结合自身多年临床经验,并在此基础上提出自己对高血压病机的独到见解,认为高血压病机应以肾虚为本,肝阳上亢、血瘀为标,主张以补肾平肝活血治则治疗高血压,在此理论认识指导下,杨教授结合自身临床经验独创经验方“双石汤”。多年临床观察研究表明,该方降压疗效显著。
第二章杨群玉教授临床经验、学术思想总结
1学术思想总结
杨师注重辨证论证,辨病、辨证结合,强调治疗个体化,对于久病顽病尤其注重活血化瘀药物的运用,提倡调畅情志,因病制宜,等,这些学术思想贯穿于其临床治疗的各方面。
2临床经验
杨师对各种内科疾病的治疗用药也因病而异,各有侧重,经验独到,值得继承发扬。
第二篇双石汤合二至丸治疗高血压肾损害的临床及机理研究
高血压病所导致的心、脑、肾等器官损害,是其致残、致死的主要原因。肾脏是高血压相关损害的重要靶器官之一。严重危害人类的健康。高血压肾损害早期,若积极治疗,肾功能是可以逆转的。因此,加强高血压病早期肾损害的研究,是目前一项重要的研究课题。开发作用缓和、持久、平稳降压且具有肾保护作用的药物为当务之急。
第一章相关文献综述
1中医学对高血压肾损害的中医病因病机、治法研究
1.1中医学对高血压肾损害尚无对应的病名。古代医家对其论述甚少,对该病尚缺乏深入、系统的认识,目前中医方面对于高血压病导致早期肾损害的理论及研究报道不多,缺乏系统性理论及防治认识。
1.2高血压肾损害中医治法多样化,有按病机立法治疗、专方治疗、名家经验、综合疗法等,而多种技术和方法的综合运用是其主要的趋势和必然发展方向。
2西医对高血压肾损害的研究进展
高血压肾损害的病因复杂。利用检测尿微量白蛋白等比较敏感的指标早期检测肾损害对该病早期诊治、预防进展有极其重要的作用,其治疗原则主要是重视高血压病的防治,且要求个体化。其防治的最终目的是控制危险因素,保护靶器官,提高患者的生存率。
3双石汤临床研究
杨群玉教授根据临床多年经验,创立了双石汤组方,以滋阴潜阳、熄风活血通络为治疗原则,是治疗高血压病的有效方药。临床研究亦表明该方具有保护血管内皮功能、改善胰岛素抵抗、降低血液流变学指标,调脂等功能,且由于照顾到高血压患者虚实夹杂的实际情况,对中医证候改善疗效更加显著。
4二至丸临床研究
二至丸原载《医方集解》由女贞子、旱莲草按1：1的比例组成,其功能为滋养肝肾。临床上多用其加减治疗各种肾脏疾病。
第二章双石汤合二至丸治疗高血压肾损害的临床及机理研究
在导师的指导下,本研究结合中医基础理论与现代医学知识,根据高血压病早期肾损害的临床特点,提出了高血压病早期肾损害为“肝肾阴虚,阳亢风动,瘀阻肾络”的病机说。以滋补肝肾、平肝熄风、活血通络为治疗大法,拟双石汤合二至丸治疗,同时,在此基础上,进一步研究其与脂联素的关系,以初步探讨其降压保肾的作用机制。
目的：
观察双石汤合二至丸治疗原发性高血压病早期肾损害的疗效及其与脂联素的关系。拟进一步验证其降压及逆转高血压所致肾损害的作用,初步探索其治疗作用的可能机理。
方法：
将60例符合标准的高血压病早期肾损害患者随机分为试验组30例,对照组30例。两组在常规治疗基础上,对照组予洛丁新片治疗,试验组在对照组基础上加用双石汤合二至丸治疗,12周为一疗程,观察治疗前后血压、临床症状、尿微量蛋白、血脂、血液流变学及血清脂联素的变化。
结果：
两组治疗前性别、年龄、体重及体重指数、饮食习惯、病程、并发疾病、血压水平、血压分级、血压危险度分层、中医单项症状等一般资料比较,差异均无显著性意义(P>0.05)。资料分析表明,治疗前两组基线基本一致,具有可比性。
试验组总有效率93.3%；对照组总有效率86.7%,试验组降压疗效优于对照组(P<0.05)。血压变化方面,试验组与对照组均有助于降低血压(P<0.05)；治疗6周后两组间收缩压和舒张压比较,差别无统计学意义(P>0.05)；治疗12周后两组间比较,试验组效果优于对照组(舒张压P<0.05,收缩压P<0.01)。症状变化方面,试验组能显著改善中医症候,疗效优于对照组(P<0.01)。研究同时显示,双石汤合至丸能显著降低尿微量蛋白的排出量(P<0.05～0.01),改善脂代谢(P<0.01),及血液流变学(P<0.05～0.01),试验组疗效明显优于对照组,且用药安全、不良反应少。本研究发现双石汤合二至丸组血清脂联素较对照组显著增高(p<0.05),表明双石汤合二至丸能促进血清脂联素的生成与释放。
结论：
双石汤合二至丸具有平稳、缓和的降压作用,并能逆转高血压病早期肾损害,改善临床症状,其作用是通过多个环节、多个靶点而综合实现的,是治疗高血压病早期肾损害的有效方剂。并且双石汤合二至丸降压保肾作用可能与血清脂联素有关。
本研究继承并发扬导师经验,从理论上深化了中医学对高血压病肾损害的病机的认识,为逆转高血压病早期肾损害提供了新的研究思路和治疗方药,为丰富高血压病的中医治疗做了有益的尝试。同时,首次研究双石汤合二至丸降压保肾作用与脂联素的关系,以初步探讨该方降压保肾的作用机制,具有一定理论意义。
Articlel summary of professor yang qunyu's clinical exper iences and academic thought
Chapter Ⅰ summary of traditional chinese medicine's research into hypertension
The shape and develop of hypertension's etiology and pathogenesis has experienced "the upper shortage leads to dizzy state ","The wind, hot, sputum leads to dizzy state ","Blood stasis leads to dizzy state ", and the theory is perfected gradually. in the recent years. the study of etiology amd pathogenesis of hypentension has been deeply researched constantly. Combining her own clinical experiences with the inspiration of the above ancients'and colleagues'experiences, professor yang qunyu puts forward her own original opinion on pathogenesis of hypentension, which thinks that Xu of the kidney is the fundamental cause of hypertension, liver-yang hyperactivity and blood stasis is its sign, insists that the principle of treating hypertension is to tonify kidney, flat liver, and invigorate the circulation of blood. under the guidance of the theory, professor yang has created her prescription "Shuang Shi Tan " on the basis of her own clinical experiences. the clinical obserservation and research for years shows that the prescription has good effect on lowering blood pressure
Chapter Ⅱ summary of professor yang qunyu's clinical experiences and academic thought
1. summary of professor yang's academic thought
professor yang emphasizes Treatment based on Syndrome differentiation combining disease di fferent iation with Syndrome differentiation and Treatment tailored to the individual. she places emphasis on the use of Chinese medicine for activating blood circulation and eliminating stasis when she cures macronosia. she advocates Widening the sentiment, treating due to illness condition, and so on. these academic thoughts can be seen through out all aspects of her clinical treatment
2. professor yang's linical experiences
professor yang treats medical disease due to illness condition, her original experiences are worth inheriting and promoting
Article Ⅱ The Clinic and Mechanism Study on ShuangShiTangandErZhiWan Prescription in Treating Early Renal Damage in Essential Hypertension
damage of heart, brain and kidney caused by hypertention is the main reason that leads to disablement and death. hypertention threatens the health of human being severely. during the early renal damage in Essential Hypertension, if active efforts are made, the function of kidney can be reversed therefore, it is an important research problem to strengthen the research into the early renal damage at present. and it is urgent to develop renal protection medicine which can lower blood pressure lastingly and smoothly
Ⅰ. reviews of literature
1. Chinese traditional medicine's study on the etiology, pathogenesis and treatment of the renal damage in Essential Hypertension.
(1) In Chinese traditional medicine, renal damage in Essential Hypertension has not a corresponding name, physicians in history had little statement on it, and their record is short of deep and systemic understanding. at present, early renal damage in Essential Hypertension in Chinese traditional medicine theory is seldom reported, let alone systematic treantment and prediction
(2) Treatment on renal damage in Essential Hypertension is varied in Chinese tradional medicine, the comprehensive use of varied technology and methods is the main tendency and invevitable development trend
2. Western medicinel understanding in renal damage in Essential Hypertension
The etiology of renal damage in Essential Hypertension is complex. by testing microalbuminuria and other more sensitive index for the disease, renal damage in Essential Hypertensioncan can be detected and prevented early, The principles of treatment is mainly attached to the prevention and control of hypertension, and require individuation. The ultimate goal is to control the risk, protect target organ, improve patients' surial rates.
3. clinical research into Shuang Shi Tang
based on the clinical experiences, Professor Yang Qunyu created the formula of ShuangShi Tang, which is to increase Ying and Reduce Yang, extinguish the wind, promote the circulation of blood. It is an effective method to cure hypertention. clinical research also shows that the prescription can protect endothelial, improve insulin resistance, reduce hemorheology indices, lipid, and so on. As to the actual situation of patients with hypertension, to TCM syndrome, the prescription's effect is more significant.
4. clinical research of Er Zhi Wan
Er Zhi Wan originally appeared in "Yi Fang Ji Tie". it is make up by fructus ligustri lucidi and Eclipta alba extract according to the ratio of one to one. Its function is to nourish liver and kidney. it is used to treat different kinds of kidney disease in the clinical treatment by adding or substracting to the prescription.
Ⅱ. The Clinic and Mechanism Study on ShuangShiTangandErZhiWan Prescription in Treating Early Renal Damage in Essential Hypertension
Under the guidance of tutor, this study combines the basic theory of TCM and modern medical knowledge with the clinical characteristics of renal damage in Essential Hypertension, concludes that the clinical characteristics of renal damage in Essential Hypertension is that Yin deficiency in liver-kidney, Yang strong and blood stasis in kidney collaterals. with ShuangShiTangandErZhiWan in treatment, which can nourish the patient's liver and kidney, flat liver, extinguish the wind, and promote the circulation of blood to remove collaterals obstruction in the kidney meanwhile, clinical observation is necessary. Based on this, we will Further research the relationship between the prescription and adiponectin. Preliminary discusses the the prescription's mechanism of lowering blood pressure and Protecting kidneys.
Objective
To observe the clinical effect of ShuangShiTangandErZhiWan to treat early renal damage in Essential Hypertension, and the relationship between the prescription and adiponectin.to Probe the effect of the prescription' lowering blood pressure and reversing the renal damage in Essential Hypertension, to Preliminary explore the possible mechanism of the prescription's Therapy effect.
Methods
60patients of Early Renal Damage in Essential HyPertension were divided into two groups at random, they are the treatment group (30cases)and the control group(30cases). Each group is given conventional treatments, the control group is given the BenazeprilHydrochlorideTablets, then the treatment group is added ShuangShiTangandErZhiWan. and12weeks for one period of treatment. the change of blood pressure, the clinical symptoms, the urinary microalbumen excretion, blood lipid, blood rheology and blood adiponectin were observed before and after treatment
Results
there are no significant differences in the two groups's gender, age, body weight and body mass index, dietary habits, course of disease, concurrent disease, blood pressure levels, blood pressure classi f'ication, blood pressure risk stratification and single symptoms before treatment (P>0.05).the information analysis shows that the two group are basically on the same baseline before treatment, their results are comparable.
The total effective rate of the treatment group is93.3%; and the control group is86.7%. the treatment group can lower blood pressure obviously more than the treatment group (p<0.01). as for the blood pressure change, both group can lower blood pressure (P<0.05), and there is no difference between two groups in6weeks, but the treatment group is better than the control group in12weeks (P<0.05~0.01). The study also shows that the prescription can lowerurinary microalbumen excretion significantly (p<0.05^0.01), improve lipid metabolism(p<0.01), Hemorheology (p<0.05-0.01), and improve adiponectin (p<0.05). its efficacy is obvious better than the control group, meanwhile can markedly improve systemic symptom (p<0.01). And the medicine is safe, fewer side effects.
Conclusions
ShuangShiTang and ErZhiWan has smooth, moderate effect on lowering blood pressure, and can reverse early renal damage in Essential Hypertension, improve the clinical symptoms. Its effect come true through multiple links and multiple targets, the medicine is an effective prescription to treat early renal damage in Essential Hypertension. Besides, ShuangShiTang and ErZhiWan's function of lowering blood and protecting kidney may be connected with Serum adiponectin
This study, which inherited and carried forward my tutor's experiences has deepened theoretically the knowledge in TCM pathogenesis of early renal damage in Essential Hypertension, it provides a new kind of research idea and Treatment agent for reversion of early renal damage in Essential Hypertension, and made a beneficial attempt to enrich Chinese medicine treatment. and for the first time, to study the relationship between the prescription and adiponectin. to Preliminary explore the possible mechanism of the prescription's effect on lowering blood pressure and reversing early renal damage in Essential Hypertensionm. so, it has some degree of theoretical significance.
引文
[1]陈香美.高血压病引起的肾脏损害[J].中华肾脏病杂志,2005,21(10)：563-565.
[2]黄颂敏,欧三桃.高血压病肾损害的诊断及治疗.[J]中华肾脏病杂志,2005,21(10)：567-568.
[3]梁贤栋,刘龙民,朱喜英.中医药治疗高血压肾损害研究进展[J].长春中医药大学学报,2009,25(3)：456-457
[4]麦志广,杨群玉.双石汤与松龄血.脉康治疗原发性高血压疗效比较[J].广州医学院学报,2005,33(5)：55-57.
[5]朱琳,杨群玉,麦志广,等.“双石汤”对高血.压病患者降压疗效及胰岛素抵抗影响的临床研究[J].江苏中医药,2008,40(2)：24-25.
[6]麦志广,朱琳,杨群玉.双石汤对高血压病血管内皮功能保护作用的临床研究.[J]湖北中医杂志,2006,28(7)：11.
[7]刘中勇,邹国辉,唐娜娜,等.平肝潜阳化痰祛瘀法对高血压病患者的颈动脉内膜中层厚度的影响[J].中国循证心血管医学杂志,2011,3(3)：207-210.
[8]王晓毅,谢志强,陈婉华,等.六君子汤治疗气虚痰瘀型高血.压病30例[J].中国中医药现代远程教育,2011,9(14)：37-38.
[9]鞠会先,干保奇,殷子杰.活血化瘀法对原发性高血压病患者血压变异性的影响[J].河南中医,2011,31(10)：1159-1160.
[10]胡小勤,曾学文,唐亚平,等,补阳还五汤、天麻钩藤饮与高血压病气虚血瘀证、肝阳上亢证关联性研究[J].中国实验方剂学杂志：志,2011,17(18)：203-205.
[11]马清钧,王淑玲等.临床实用中药学[M].南昌：江西科学技术出版社,2002,第1版.
[12]雷载权,张廷模等.中华临床中药学[M].北京：人民卫生出版社,1998,第1版.
[13]凌一揆,颜正华等.中药学[M].上海：上海科学技术出版社,1999,第5版.
[14]高学敏.中药学[M].北京：中国中医药出版社,2007,第2版：75,297,325,397,401,409,411,445,629-630.
[15]周程艳等.钩藤碱的药理学研究进展[J].华北煤炭医学院学报,2002；4(4)：447～448.
[16]吴杲,何招兵,吴汉斌.丹参酮的药理作用研究进展[J].现代中西医结合杂志,2005,14(10)：1382-1384.
[17]彭招华,袁侣明,韩民利.丹参的药理作用研究概况[J].中药材,2001,24(9)：690—693.
[18]罗季安.丹参、蒲黄、大黄制剂对大鼠草鱼胆中毒早期肾损害的影响[J].中国中西医结合杂志,1993,13(3)：98.
[19]刘金波,邓华聪,葛倩,等.脂联素对TNF-α介导的血.管炎症反应的影响[J].第四军医大学学报,2006,27：1697-1699.
[20]徐向青,郑三霞.高血压病肾损害病机简析[J].中医药学刊,2005,23(1)：312—313.
[21]程广书.高血压肾损害的中医药治疗思路[J].河南中医,2001,21(1)：29-31.
[22]孟伟,高红春.滋阴降火通络汤治疗高血压病早期肾损害的临床研究[J].山东中医药大学学报,2003,27(5)：364-366.
[23]仲昱,王刚,倪斌.从脾肾认识高血.压肾损害的发展演变规律[J].天津中医药,2005,22(2) ： 111.
[24]韩彬.肾性高血.压基本方[J].中国中西医结合结合肾病杂志,2001,2(5)：302-302.
[25]叶景华.治疗肾性高血压经验[J].湖南中医杂志,1997,13(4)：2122.
[26]关广聚,梁玉环,吴涛,等.血管紧张素转换酶基因D/I多态性与高血压肾损害的关系[J].中华肾脏病杂志,2001,17(2)：126.
[27]宋艳丽,陈义汉,徐文渊.血浆PAI-1水平及其基因多态性与高血压肾损害的关系[J].铁道医学,2000,28(1)：6.
[28]林善锬.当代肾脏病学[M].上海：上海科技教育出版社,2001.684.
[29]欧亚龙,彭素岚,徐应杼.高血压病与血瘀关系的实验观察[J].四川中医,1991,9(6)3-4.
[30]王崇行.高血.压心气虚血瘀型病理生理学基础及气功治疗[J].中国中两医结合杂志,1995,15(8)：454.
[31]李运伦,姚晓渝.补肾方对老年人高血压的影响[J].中国医药学报,1999,14(5)：26—28
[32]曲智勇.补肾方治疗中老年原发性高血压早期肾损害临床研究[J].山东中医药,2008,27(8)：513.
[33]徐向东,徐向青,侯秀娟.益肾方对自发性高血压大鼠肾脏保护作用的研究[J].辽宁中医杂志,2004,31(7)：615.
[34]武可文.中西医结合治疗高血压肾损害临床观察[J].湖北中医杂志,2005,27(7)：11
[35]张晓斌,孔德坤,付明.丹黄降氮汤治疗高血压病早期肾功能损害[J].山东中医杂志,2008,27(4)：234-235
[36]何有为.益肾活血法治疗高血压肾损害临床观察[J].湖北中医杂志,2007,29(5)：32.
[37]顾健霞.周氏养肝益水颗粒减轻原发性高血压早期肾损害的作用观察[J].中医药临床杂志,2005,17(4)：373374.
[38]顾仁樾.中医药防治高血压病靶器官损伤临床体会[J].江苏中医药,2007,39(10)：6-7.
[39]范群丽,赵东杰,唐蜀华.降压益肾颗粒治疗高血压病早期肾损害临床观察[J].南京中医药大学学报,2003,19(5)：8-9.
[40]邓宝华,高血压性肾损害早中期的中医证治体会[J].光明中医,2009,24(1)：111-112.
[41]施志琴,麻志恒.补肾化浊汤联合中药灌肠治疗高血压肾功能不全疗效观察[J].上海中医杂志,2008,42(5)：40
[42]王清海,卢桂梅,李爱华等.血压健胶囊治疗气虚痰浊型高血压的临床研究[J].新中医,1998;30(1)：35-36.
[43]杨运清.天麻地黄饮降压及干预高血压病肾损害66例观察[J].陕西中医,2007,28(7)835-837.
[44]胡宗仁,刘龙民,朱喜英.益肾平肝方治疗原发性高血压早期肾损害的临床疗效[J].吉林中医药,2008,28(7)：490-491.
[45]徐宏,关建国,等,滋肾潜阳活血法治疗高血压早期肾损害37例临床观察[J].辽宁中医杂志,2006,33(12)：1584-1585.
[46]周婷.中西药结合高血.压早期肾损害临床研究[J].四川中医,2007,25(8)：8-9.
[47]孟伟.中西医结合治疗高血.压肾损害[J].中医研究,2003,16(6)：29—30.
[48]张彬.论气虚血.瘀在高血压肾损害发病过程中的作用[J].上海中医药大学学报,2005,19(4)：11-12.
[49]张森.天麻芍莲汤降压及对高血压病肾损害的干预作用[J].林床和实验医学杂志,2007,6(10)： 134.
[50]郭志军,高秀梅,康利源,等.养血清脑颗粒对SHR对RAS的影响[J].山西中医学院学报,2006,7(2)：9.
[51]陶永,杨帆,戴小华,等.养肝益水颗粒对原发性高血压早期肾损害患者肾叶间动脉血流的影响[J].安徽中医学院学报,2007,26(4)：8-9.
[52]张天斗,李承禧.六味地黄丸对老年性高血.压患者肾保护作用的临床研究[J].世界科学技术-中医药现代化,2006,8(2)：102-104
[53]徐洪波.叶任高教授治疗高血压肾损害的临证经验[J].中国中西医结合肾病杂志,2000,12(4)：200-201.
[54]王钢,陈以平,邹燕勤.现代中医肾脏病学[M].北京：人民卫生出版社,2003：3.
[55]张英.不同疗法对二肾-夹型高血.压大鼠血.管紧张素、心钠素含量影响的比较[J].中国针灸,1996,(5)：35-37
[56]张琪.灌肠液治疗高血压患者早期肾脏损害60例[J].南京中医药大学学报(自然科学版),2001, 17(3)：189-190
[57]曹阳.中药穴位注射治疗高血压性肾损害临床观察[J].中国针灸,2005,25(1)：21.
[58]Poursh JG Hypertension and chronic renal failure, the use of ACE inhibitors[J]. Am J Kindey Dis,1998,31 (1):177-184.
[59]王世荣,平高华,中医治未病思想在高血压肾损害防治中的运用思路[J],中西医结合心脑血管病杂志,2009,7(10)：1211.
[60]江时森,朱永吕,李俭春等.高血压病不同时期对肾脏的损害[J].中华心血管杂志,1988,16(5)：261-263
[61]黄峻,陆凤翔.实用内科诊疗规范[M].南京：江苏科学技术出版社,2003,3： 228-230.
[62]袁伟杰,崔若兰.对高血.压肾损害临床应进一步思考的问题[J].中华肾脏病杂志,2005,21(10)：572.
[63]Palmer BE. Impaired renal autoregulation:impl ication for the genesis of hyPertension and hypertension-induced renal injury[J]. Am J Med Sci,2001,321:388-400.
[64]Anderson Wp, Kett MM, Stevenson KM, et al. Renovaseular hypertension:structural changes in the renal vasculature[J]. Hypertension,2000,36:648-652.
[65]顾勇.高血压肾损害[J].临床肾脏病杂志,2002,2(3)：147-151.
[66]戴瑞鸿,林果为,林庚金,等.内科学新理论与新技术.[M]上海：上海科学教育出版社,2002,3：359-360.
[67]Kincaid-Smith P. Hypothesis:obesity and the insul in resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled hypertensive nephrosclerosis'[J]. J Hypertens,2004,22:1051-1055.
[68]付治卿,周聊生.高血压肾损害机制的探讨[J].临床荟萃,2004,19(8)：469-471.
[69]郑剑卿,谢秀梅,余国龙.氯沙坦对老年轻、中度原发性高血压的肾脏保护作用[J].湖南医学,2000,17(6)：169-172.
[70]董光富,叶任高.等.纤溶活性及D-二聚体变化与老年高血压肾损害关系的研究[J].中华老年医学杂志,2000。19(2)：112一114.
[71]赵林双,廖玉华,王敏等.血清抗AT1、α1、β1受体自身抗体在高血压合病肾损害患者的初步研究[J].高血压杂志,2006,14(3)：181-184.
[72]Toru A, Nobukazu I, Kiyoshi K, et al.Different effeets of angiotensin Hand cateeholamine on renal cell apoptosis and proliferation in rats[J].Kidney Int,2001, 59:645-653.
[73]陈学清,徐光来,张亚萍,等.高血压家族史对高血压病患者肾损害的影响[J].浙江中西医结合杂志,2007,17(2)：80.
[74]李行勇.尿微量蛋白在原发性高血压肾损害早期诊断中的意义[J].实用医技杂志,2004,11(10)：2109-2120.
[75]李招云,吴晓宇,赖卫强等.高血.压病患者肾脏早期损害指标的探讨[J].中华检验医学杂志,2001,24(5)：282～284.
[76]邱清芳.尿微量蛋白检测在高血压肾损害早期诊断中的应用[J].四川医学,2002,23(7)：726-727.
[77]周建光,杨梅.尿微量白蛋白的临床检验意义及诊断价值[J].实用医技杂志,2008,15(5)：578-579.
[78]李庆祥,徐方兴,王炬,等.原发性高血压患者尿β 2微球蛋白检测的临床意义[J].中国综合临床,2006,22(4)：300-301.
[79]沈丹,哈黛文.血与尿β 2-微球蛋白、免疫球蛋白G及尿白蛋白在老年高血压病患者中的应用[J].中国综合临床,2003,19(1)：33-34.
[80]于江月,李树青.高血.压早期肾损害的检测方法[J].医学综述,2006,12(13)：828.
[81]李萍,贾天军,王立新,等.尿微量蛋白联合尿酶诊断高血压早期肾损害[J].中国心血管杂志,2002：7(6)：407.
[82]李竞,包艳,甘佩珍.糖尿病肾病患者血及尿转铁蛋白测定的临床意义[J].临床内科杂志,2002,19(6)：454-455.
[83]高学慧,李倩,甘勇,等.尿微量蛋白在早期肾脏损伤中的临床应用[J].陕西医学检验,2001,16(2)：44-45.
[84]国献书,吕衡.高血压性肾损害早期患者动态血压规律的改变.青岛医药卫生,2002：34(3)：180～181.
[85]许红强,王金萍,常丽娜.肾叶间动脉阻力指数与原发性高血压早期肾损害的相关性[J].安徽中医学院学报,2006,25(4)：51.
[86]王国芳,张建立,倪秋杰,等.超声多普勒肾血流测定对Ⅰ期高血压病肾损害的研究[J].中国超声诊断杂志,2002：3(9)：687-688.
[87]向莉.肾显像早期诊断原发性高血压肾损害的临床价值[J].河北医学,2004,10(3)：207.
[88]李宝亮,杨桂芬,明秀峰.尿微量蛋白联合尿酶诊断高血压病肾脏早期损伤[J].河北北方学院学报(医学版),2005,22(1)：67-68.
[89]Nakao N, Yoshim ura A, M orita H. et al. Combination treatment of angiotensin Ⅱ receptor blocker and angiotensin converting-enzyme inhibitor in non—diabetic renal disease (COOPER—ATE):a randomised controlled trial [J]. Lancet,2003,361:117-124.
[90]万建新,吴可贵,林金秀,等.氯沙坦和苯那普利联合治疗肾性高血压的临床研究[J].中华心血.管病杂志,2003,31：413—416.
[91]王力宁,姚丽.高血压性肾损害[J].中华肾脏病杂志,2005,21(10)：569-571.
[92]Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte -derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population[J]. Clinical Science,2002,103 (2):137.
[93]Hirsch AT, Vascular disease, hypertension, and prevention:from en-dothelium to clinical events [J].Jacc,2003,42 (2):377-379.
[94]Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients [J]. Circulation,2001,104:191-19
[95]Widansky ME, Glkce N, Keaney JF, et al.The clinica limplica-tions of endothelial dysfunction[J].J Am Coll Cardiol,2003,42:1149-1160.
[96]吕冬宁.二至丸在肾脏疾病中的应用举隅[J].江苏中医药,2006,27(9)：52-53.
[97]柴茂山.中西结合治疗小儿过敏性紫癜肾炎106例[J].中国中医药信息杂志,2007,14(1)：66-67.
[98]谢恂.滋肾调肝法治疗Ig肾病血尿39例的临床观察[J].中华临床医学研究杂志,2008,14(3)：379-380.
[99]周小琳,杨运清.止血滋肾丸为主治疗IgA肾病68例临床观察[J].四川中医,2004,22(5)：51.
[100]刘志红,黎磊石.狼疮肾炎的治疗[J].中国实用内科杂志,2006,26(2)：86-87
[101]杨林,成慧贞.中西医结合治疗狼疮性肾炎36例临床研究[J].河北中医,2003,25(9)698-700.
[102]胡赘,詹继红.二至丸合三仁汤治疗慢性肾炎23例[J].实用中医药杂志,2006,22(5)281.
[103]徐艳秋,李玉波,包志魁.中医药在原发性肾病综合征激素治疗中的地位和作用[J].中医药学报,2007,35(3)：24-25.
[104]高振中,张致远.养阴祛浊汤治疗慢性肾衰竭43例[J].山东中医杂志,2005,24(12)724.
[105]黄红勤.中药内服配合灌肠治疗慢性肾功能衰竭[J].中原医刊,2006,33(13)：70-71
[106]董兴刚,陈志英.叶任高教授治疗氮质血症的临床经验[J].中国中西医结合肾病杂志,2004,5(3)：129-130.
[107]操红缨,谈博.二至丸对小鼠巨噬细胞产生IL-1的影响[J].中药新药与临床药理,2000,11(3)：154-156.
[108]刘大基,刘解生,徐继勋,等.二至丸对小鼠淋巴细胞免疫功能的调节作用[J].湖北中医杂志,2002,24(2)：48-49.
[109]操红缨,梁颂名,荣向路,等.二至丸对阴虚模型神经内分泌免疫网络调节作用的研究[J].中药材,2000,23(3)：164～166.
[110]丁安伟,王苏玲,孔令东,等.二至丸及其处方炮制品的药理作用[J].中国中药杂志.1992,17(9)：531～534.
[111]李胜志,赵雪莹,李冀.二至丸对D—半乳糖致衰老模型大鼠SOD、MDA影响的实验研究[J].中医药信息,2008,25(3)：37～38.
[112]孙洪涛.二至丸对衰老小鼠模型脑细胞Na-K-ATP酶、Ca2-ATP酶活性影响的研究.中外医疗,2008(13)：78.
[113]李弋,杨友谊.中药二至丸对老年痴呆模型小鼠脑组织Na-K-ATPase、Ca-ATPase活性及学习记忆的影响[J].广州医学院学报,2005,33(3)：23-25.
[114]王淑梅,王灿岭.二至丸对亚急性衰老模型小鼠抗衰老作用的实验研究[J].中医研究,200,19(5)：21-22.
[115]莫莉莉,李秀挺,梁颂名.防治动脉粥样硬化中草药的研究[J].新中医,1988,9(3)：33.
[116]郝志奇,杭秉茜.齐墩果酸对小鼠的降血糖作用[J].中国药科大学学报.1991,22(4)：210-212[14]女贞子降血糖作用的研究.
[117]赵雪莹,李胜志,李冀.二至丸对衰老大鼠血液流变学影响的实验研究[J].辽宁中医杂志,2008,35(6)：945～946.
[118]胡慧娟,杭秉茜.二至丸的抗炎作用[J].江西中医学院学报,1993,5(2)：37-38.
[119]窦志英,宋坤,丁安伟.二至为对四氯化碳所致小鼠ALT升高的预防作用[J].天津中医学院学报,2002,21(3)：45-46.
[121]中国高血压防治指南修订委员会.中国高血压防治指南(2005年修订版).[M]北京：人民卫生出版社,2005.
[122]郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：75-77.
[123]黎磊,许顶立.高血压与肾脏专题座谈会纪要[J].中华内科杂志,1989,28：302—306.
[124]程文江,覃志成,郭峰,等.原发性高血压病602例中医证候流行病学研究[J].浙江中西医结合杂志,2003,13(4)：261.
[125]仲昱,王钢,倪斌.高血.压肾损害内风伤肾证候学研究[J].甘肃中医,2007,20(8)：24-25
[126]冯国标.中西医结合治疗肾性高血压96例观察[J].实用中医药杂志,2001,17
[127]杨帆,戴小华,王建彬.原发性高血压早期肾损害中医证候学观察[J].安徽中医学院学报.2007,26(2),8-11
[128]程十德.内经[M].北京：人民出版社,1987,第1版：55
[129]唐洪波.女贞子善治冠心病及眩晕症[J].中华养生保健,2004;(8)：43
[130]尚伟芬,于澎仁.天麻药理作用研究进展[J].中草药,1997,25(10)：629-630.
[131]林泽鹏,徐明星,方卫华,原发性高血压患者血清脂联素浓度的变化及肾素一血.管紧张素系统对其影响[J],中国循环杂志,2004,19(3)：205-207
[132]Yoshio I, Tomohiro K, Kazuhikol, et al. Hypoadiponectinemiais an independent risk factor for hypertension[J]. Hypertension,2004,43:1318-1323.
[133]lwashima Y, Katsuya T, Ishiawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension[J]. Hypertension,2004; 43:1318-23.
[134]周淑娴,雷娟,张玉玲,等,高血压患者胰岛素抵抗与血.清脂联素及炎症标志物水平[J],中华高血.压杂志.2008,16(2)：166-170
[135]李嘉强,戴颖秀,刘玉敏,等.高血压患者血清脂联素与游离脂肪酸、糖及脂代谢[J].高血压杂志,2006,14.352—355.
[l36]Wang Y, Lam KS, XuJY, et al. Adiponectin inhibits cellproliferation by interacting with several growth factors in anoligomerization-dependent manner[J]. J Biol Chem,2005, 280 (18):18341-18347.
[137]Danesh J, Wheeler JG, Hirschfield GM, et al. Oreactive proteinand other circulating markers of inflammation in the prediction ofcoronary heart disease [J]. N Engl J Med 2004:350:1387-1397.
[138]Pearson TA, Mensah GA, Alexander RW, et al. Markers ofinflammation and cardiovascular disease:application to clinical andpublic health practice:a statement for healthcare professionals from theCenters for Disease Control and Prevention and the American HeartAssociation[J]. Circulation 2003:107:499-511.
[139]Libby P, Willerson JT, Braunwald E. C-reactive protein and coronary heart disease. N Engl J Med 2004:351:295-296.
[140]崔倩卫,冷吉燕,卜丽梅,高血压伴胰岛素抵抗患者血清脂联素水平与动脉粥样硬化的相关性研究[J],中国老年医学杂志2011,6(31)：1959-1960
[141]Tsioufis C, Dimitradis K, Selima M, et al. Low—grade inflamma—tion and hypoadiponectinaemia have an additive detrimental effecton aortic stiffness in essential hypertensive patientsr[J]. Eur HeartJ,2007,28:1162 1169.
[142]Fantuzzi G. Adipose tissue, adipokines, and inflammation [J]. JAllergy Clin Immunol, 2005,115:911-920.
[2]黄颂敏,欧三桃.高血压病肾损害的诊断及治疗.[J]中华肾脏病杂志,2005,21(10)：567-568.
[3]梁贤栋,刘龙民,朱喜英.中医药治疗高血压肾损害研究进展[J].长春中医药大学学报,2009,25(3)：456-457
[4]麦志广,杨群玉.双石汤与松龄血.脉康治疗原发性高血压疗效比较[J].广州医学院学报,2005,33(5)：55-57.
[5]朱琳,杨群玉,麦志广,等.“双石汤”对高血.压病患者降压疗效及胰岛素抵抗影响的临床研究[J].江苏中医药,2008,40(2)：24-25.
[6]麦志广,朱琳,杨群玉.双石汤对高血压病血管内皮功能保护作用的临床研究.[J]湖北中医杂志,2006,28(7)：11.
[7]刘中勇,邹国辉,唐娜娜,等.平肝潜阳化痰祛瘀法对高血压病患者的颈动脉内膜中层厚度的影响[J].中国循证心血管医学杂志,2011,3(3)：207-210.
[8]王晓毅,谢志强,陈婉华,等.六君子汤治疗气虚痰瘀型高血.压病30例[J].中国中医药现代远程教育,2011,9(14)：37-38.
[9]鞠会先,干保奇,殷子杰.活血化瘀法对原发性高血压病患者血压变异性的影响[J].河南中医,2011,31(10)：1159-1160.
[10]胡小勤,曾学文,唐亚平,等,补阳还五汤、天麻钩藤饮与高血压病气虚血瘀证、肝阳上亢证关联性研究[J].中国实验方剂学杂志：志,2011,17(18)：203-205.
[11]马清钧,王淑玲等.临床实用中药学[M].南昌：江西科学技术出版社,2002,第1版.
[12]雷载权,张廷模等.中华临床中药学[M].北京：人民卫生出版社,1998,第1版.
[13]凌一揆,颜正华等.中药学[M].上海：上海科学技术出版社,1999,第5版.
[14]高学敏.中药学[M].北京：中国中医药出版社,2007,第2版：75,297,325,397,401,409,411,445,629-630.
[15]周程艳等.钩藤碱的药理学研究进展[J].华北煤炭医学院学报,2002；4(4)：447～448.
[16]吴杲,何招兵,吴汉斌.丹参酮的药理作用研究进展[J].现代中西医结合杂志,2005,14(10)：1382-1384.
[17]彭招华,袁侣明,韩民利.丹参的药理作用研究概况[J].中药材,2001,24(9)：690—693.
[18]罗季安.丹参、蒲黄、大黄制剂对大鼠草鱼胆中毒早期肾损害的影响[J].中国中西医结合杂志,1993,13(3)：98.
[19]刘金波,邓华聪,葛倩,等.脂联素对TNF-α介导的血.管炎症反应的影响[J].第四军医大学学报,2006,27：1697-1699.
[20]徐向青,郑三霞.高血压病肾损害病机简析[J].中医药学刊,2005,23(1)：312—313.
[21]程广书.高血压肾损害的中医药治疗思路[J].河南中医,2001,21(1)：29-31.
[22]孟伟,高红春.滋阴降火通络汤治疗高血压病早期肾损害的临床研究[J].山东中医药大学学报,2003,27(5)：364-366.
[23]仲昱,王刚,倪斌.从脾肾认识高血.压肾损害的发展演变规律[J].天津中医药,2005,22(2) ： 111.
[24]韩彬.肾性高血.压基本方[J].中国中西医结合结合肾病杂志,2001,2(5)：302-302.
[25]叶景华.治疗肾性高血压经验[J].湖南中医杂志,1997,13(4)：2122.
[26]关广聚,梁玉环,吴涛,等.血管紧张素转换酶基因D/I多态性与高血压肾损害的关系[J].中华肾脏病杂志,2001,17(2)：126.
[27]宋艳丽,陈义汉,徐文渊.血浆PAI-1水平及其基因多态性与高血压肾损害的关系[J].铁道医学,2000,28(1)：6.
[28]林善锬.当代肾脏病学[M].上海：上海科技教育出版社,2001.684.
[29]欧亚龙,彭素岚,徐应杼.高血压病与血瘀关系的实验观察[J].四川中医,1991,9(6)3-4.
[30]王崇行.高血.压心气虚血瘀型病理生理学基础及气功治疗[J].中国中两医结合杂志,1995,15(8)：454.
[31]李运伦,姚晓渝.补肾方对老年人高血压的影响[J].中国医药学报,1999,14(5)：26—28
[32]曲智勇.补肾方治疗中老年原发性高血压早期肾损害临床研究[J].山东中医药,2008,27(8)：513.
[33]徐向东,徐向青,侯秀娟.益肾方对自发性高血压大鼠肾脏保护作用的研究[J].辽宁中医杂志,2004,31(7)：615.
[34]武可文.中西医结合治疗高血压肾损害临床观察[J].湖北中医杂志,2005,27(7)：11
[35]张晓斌,孔德坤,付明.丹黄降氮汤治疗高血压病早期肾功能损害[J].山东中医杂志,2008,27(4)：234-235
[36]何有为.益肾活血法治疗高血压肾损害临床观察[J].湖北中医杂志,2007,29(5)：32.
[37]顾健霞.周氏养肝益水颗粒减轻原发性高血压早期肾损害的作用观察[J].中医药临床杂志,2005,17(4)：373374.
[38]顾仁樾.中医药防治高血压病靶器官损伤临床体会[J].江苏中医药,2007,39(10)：6-7.
[39]范群丽,赵东杰,唐蜀华.降压益肾颗粒治疗高血压病早期肾损害临床观察[J].南京中医药大学学报,2003,19(5)：8-9.
[40]邓宝华,高血压性肾损害早中期的中医证治体会[J].光明中医,2009,24(1)：111-112.
[41]施志琴,麻志恒.补肾化浊汤联合中药灌肠治疗高血压肾功能不全疗效观察[J].上海中医杂志,2008,42(5)：40
[42]王清海,卢桂梅,李爱华等.血压健胶囊治疗气虚痰浊型高血压的临床研究[J].新中医,1998;30(1)：35-36.
[43]杨运清.天麻地黄饮降压及干预高血压病肾损害66例观察[J].陕西中医,2007,28(7)835-837.
[44]胡宗仁,刘龙民,朱喜英.益肾平肝方治疗原发性高血压早期肾损害的临床疗效[J].吉林中医药,2008,28(7)：490-491.
[45]徐宏,关建国,等,滋肾潜阳活血法治疗高血压早期肾损害37例临床观察[J].辽宁中医杂志,2006,33(12)：1584-1585.
[46]周婷.中西药结合高血.压早期肾损害临床研究[J].四川中医,2007,25(8)：8-9.
[47]孟伟.中西医结合治疗高血.压肾损害[J].中医研究,2003,16(6)：29—30.
[48]张彬.论气虚血.瘀在高血压肾损害发病过程中的作用[J].上海中医药大学学报,2005,19(4)：11-12.
[49]张森.天麻芍莲汤降压及对高血压病肾损害的干预作用[J].林床和实验医学杂志,2007,6(10)： 134.
[50]郭志军,高秀梅,康利源,等.养血清脑颗粒对SHR对RAS的影响[J].山西中医学院学报,2006,7(2)：9.
[51]陶永,杨帆,戴小华,等.养肝益水颗粒对原发性高血压早期肾损害患者肾叶间动脉血流的影响[J].安徽中医学院学报,2007,26(4)：8-9.
[52]张天斗,李承禧.六味地黄丸对老年性高血.压患者肾保护作用的临床研究[J].世界科学技术-中医药现代化,2006,8(2)：102-104
[53]徐洪波.叶任高教授治疗高血压肾损害的临证经验[J].中国中西医结合肾病杂志,2000,12(4)：200-201.
[54]王钢,陈以平,邹燕勤.现代中医肾脏病学[M].北京：人民卫生出版社,2003：3.
[55]张英.不同疗法对二肾-夹型高血.压大鼠血.管紧张素、心钠素含量影响的比较[J].中国针灸,1996,(5)：35-37
[56]张琪.灌肠液治疗高血压患者早期肾脏损害60例[J].南京中医药大学学报(自然科学版),2001, 17(3)：189-190
[57]曹阳.中药穴位注射治疗高血压性肾损害临床观察[J].中国针灸,2005,25(1)：21.
[58]Poursh JG Hypertension and chronic renal failure, the use of ACE inhibitors[J]. Am J Kindey Dis,1998,31 (1):177-184.
[59]王世荣,平高华,中医治未病思想在高血压肾损害防治中的运用思路[J],中西医结合心脑血管病杂志,2009,7(10)：1211.
[60]江时森,朱永吕,李俭春等.高血压病不同时期对肾脏的损害[J].中华心血管杂志,1988,16(5)：261-263
[61]黄峻,陆凤翔.实用内科诊疗规范[M].南京：江苏科学技术出版社,2003,3： 228-230.
[62]袁伟杰,崔若兰.对高血.压肾损害临床应进一步思考的问题[J].中华肾脏病杂志,2005,21(10)：572.
[63]Palmer BE. Impaired renal autoregulation:impl ication for the genesis of hyPertension and hypertension-induced renal injury[J]. Am J Med Sci,2001,321:388-400.
[64]Anderson Wp, Kett MM, Stevenson KM, et al. Renovaseular hypertension:structural changes in the renal vasculature[J]. Hypertension,2000,36:648-652.
[65]顾勇.高血压肾损害[J].临床肾脏病杂志,2002,2(3)：147-151.
[66]戴瑞鸿,林果为,林庚金,等.内科学新理论与新技术.[M]上海：上海科学教育出版社,2002,3：359-360.
[67]Kincaid-Smith P. Hypothesis:obesity and the insul in resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled hypertensive nephrosclerosis'[J]. J Hypertens,2004,22:1051-1055.
[68]付治卿,周聊生.高血压肾损害机制的探讨[J].临床荟萃,2004,19(8)：469-471.
[69]郑剑卿,谢秀梅,余国龙.氯沙坦对老年轻、中度原发性高血压的肾脏保护作用[J].湖南医学,2000,17(6)：169-172.
[70]董光富,叶任高.等.纤溶活性及D-二聚体变化与老年高血压肾损害关系的研究[J].中华老年医学杂志,2000。19(2)：112一114.
[71]赵林双,廖玉华,王敏等.血清抗AT1、α1、β1受体自身抗体在高血压合病肾损害患者的初步研究[J].高血压杂志,2006,14(3)：181-184.
[72]Toru A, Nobukazu I, Kiyoshi K, et al.Different effeets of angiotensin Hand cateeholamine on renal cell apoptosis and proliferation in rats[J].Kidney Int,2001, 59:645-653.
[73]陈学清,徐光来,张亚萍,等.高血压家族史对高血压病患者肾损害的影响[J].浙江中西医结合杂志,2007,17(2)：80.
[74]李行勇.尿微量蛋白在原发性高血压肾损害早期诊断中的意义[J].实用医技杂志,2004,11(10)：2109-2120.
[75]李招云,吴晓宇,赖卫强等.高血.压病患者肾脏早期损害指标的探讨[J].中华检验医学杂志,2001,24(5)：282～284.
[76]邱清芳.尿微量蛋白检测在高血压肾损害早期诊断中的应用[J].四川医学,2002,23(7)：726-727.
[77]周建光,杨梅.尿微量白蛋白的临床检验意义及诊断价值[J].实用医技杂志,2008,15(5)：578-579.
[78]李庆祥,徐方兴,王炬,等.原发性高血压患者尿β 2微球蛋白检测的临床意义[J].中国综合临床,2006,22(4)：300-301.
[79]沈丹,哈黛文.血与尿β 2-微球蛋白、免疫球蛋白G及尿白蛋白在老年高血压病患者中的应用[J].中国综合临床,2003,19(1)：33-34.
[80]于江月,李树青.高血.压早期肾损害的检测方法[J].医学综述,2006,12(13)：828.
[81]李萍,贾天军,王立新,等.尿微量蛋白联合尿酶诊断高血压早期肾损害[J].中国心血管杂志,2002：7(6)：407.
[82]李竞,包艳,甘佩珍.糖尿病肾病患者血及尿转铁蛋白测定的临床意义[J].临床内科杂志,2002,19(6)：454-455.
[83]高学慧,李倩,甘勇,等.尿微量蛋白在早期肾脏损伤中的临床应用[J].陕西医学检验,2001,16(2)：44-45.
[84]国献书,吕衡.高血压性肾损害早期患者动态血压规律的改变.青岛医药卫生,2002：34(3)：180～181.
[85]许红强,王金萍,常丽娜.肾叶间动脉阻力指数与原发性高血压早期肾损害的相关性[J].安徽中医学院学报,2006,25(4)：51.
[86]王国芳,张建立,倪秋杰,等.超声多普勒肾血流测定对Ⅰ期高血压病肾损害的研究[J].中国超声诊断杂志,2002：3(9)：687-688.
[87]向莉.肾显像早期诊断原发性高血压肾损害的临床价值[J].河北医学,2004,10(3)：207.
[88]李宝亮,杨桂芬,明秀峰.尿微量蛋白联合尿酶诊断高血压病肾脏早期损伤[J].河北北方学院学报(医学版),2005,22(1)：67-68.
[89]Nakao N, Yoshim ura A, M orita H. et al. Combination treatment of angiotensin Ⅱ receptor blocker and angiotensin converting-enzyme inhibitor in non—diabetic renal disease (COOPER—ATE):a randomised controlled trial [J]. Lancet,2003,361:117-124.
[90]万建新,吴可贵,林金秀,等.氯沙坦和苯那普利联合治疗肾性高血压的临床研究[J].中华心血.管病杂志,2003,31：413—416.
[91]王力宁,姚丽.高血压性肾损害[J].中华肾脏病杂志,2005,21(10)：569-571.
[92]Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte -derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population[J]. Clinical Science,2002,103 (2):137.
[93]Hirsch AT, Vascular disease, hypertension, and prevention:from en-dothelium to clinical events [J].Jacc,2003,42 (2):377-379.
[94]Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients [J]. Circulation,2001,104:191-19
[95]Widansky ME, Glkce N, Keaney JF, et al.The clinica limplica-tions of endothelial dysfunction[J].J Am Coll Cardiol,2003,42:1149-1160.
[96]吕冬宁.二至丸在肾脏疾病中的应用举隅[J].江苏中医药,2006,27(9)：52-53.
[97]柴茂山.中西结合治疗小儿过敏性紫癜肾炎106例[J].中国中医药信息杂志,2007,14(1)：66-67.
[98]谢恂.滋肾调肝法治疗Ig肾病血尿39例的临床观察[J].中华临床医学研究杂志,2008,14(3)：379-380.
[99]周小琳,杨运清.止血滋肾丸为主治疗IgA肾病68例临床观察[J].四川中医,2004,22(5)：51.
[100]刘志红,黎磊石.狼疮肾炎的治疗[J].中国实用内科杂志,2006,26(2)：86-87
[101]杨林,成慧贞.中西医结合治疗狼疮性肾炎36例临床研究[J].河北中医,2003,25(9)698-700.
[102]胡赘,詹继红.二至丸合三仁汤治疗慢性肾炎23例[J].实用中医药杂志,2006,22(5)281.
[103]徐艳秋,李玉波,包志魁.中医药在原发性肾病综合征激素治疗中的地位和作用[J].中医药学报,2007,35(3)：24-25.
[104]高振中,张致远.养阴祛浊汤治疗慢性肾衰竭43例[J].山东中医杂志,2005,24(12)724.
[105]黄红勤.中药内服配合灌肠治疗慢性肾功能衰竭[J].中原医刊,2006,33(13)：70-71
[106]董兴刚,陈志英.叶任高教授治疗氮质血症的临床经验[J].中国中西医结合肾病杂志,2004,5(3)：129-130.
[107]操红缨,谈博.二至丸对小鼠巨噬细胞产生IL-1的影响[J].中药新药与临床药理,2000,11(3)：154-156.
[108]刘大基,刘解生,徐继勋,等.二至丸对小鼠淋巴细胞免疫功能的调节作用[J].湖北中医杂志,2002,24(2)：48-49.
[109]操红缨,梁颂名,荣向路,等.二至丸对阴虚模型神经内分泌免疫网络调节作用的研究[J].中药材,2000,23(3)：164～166.
[110]丁安伟,王苏玲,孔令东,等.二至丸及其处方炮制品的药理作用[J].中国中药杂志.1992,17(9)：531～534.
[111]李胜志,赵雪莹,李冀.二至丸对D—半乳糖致衰老模型大鼠SOD、MDA影响的实验研究[J].中医药信息,2008,25(3)：37～38.
[112]孙洪涛.二至丸对衰老小鼠模型脑细胞Na-K-ATP酶、Ca2-ATP酶活性影响的研究.中外医疗,2008(13)：78.
[113]李弋,杨友谊.中药二至丸对老年痴呆模型小鼠脑组织Na-K-ATPase、Ca-ATPase活性及学习记忆的影响[J].广州医学院学报,2005,33(3)：23-25.
[114]王淑梅,王灿岭.二至丸对亚急性衰老模型小鼠抗衰老作用的实验研究[J].中医研究,200,19(5)：21-22.
[115]莫莉莉,李秀挺,梁颂名.防治动脉粥样硬化中草药的研究[J].新中医,1988,9(3)：33.
[116]郝志奇,杭秉茜.齐墩果酸对小鼠的降血糖作用[J].中国药科大学学报.1991,22(4)：210-212[14]女贞子降血糖作用的研究.
[117]赵雪莹,李胜志,李冀.二至丸对衰老大鼠血液流变学影响的实验研究[J].辽宁中医杂志,2008,35(6)：945～946.
[118]胡慧娟,杭秉茜.二至丸的抗炎作用[J].江西中医学院学报,1993,5(2)：37-38.
[119]窦志英,宋坤,丁安伟.二至为对四氯化碳所致小鼠ALT升高的预防作用[J].天津中医学院学报,2002,21(3)：45-46.
[121]中国高血压防治指南修订委员会.中国高血压防治指南(2005年修订版).[M]北京：人民卫生出版社,2005.
[122]郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：75-77.
[123]黎磊,许顶立.高血压与肾脏专题座谈会纪要[J].中华内科杂志,1989,28：302—306.
[124]程文江,覃志成,郭峰,等.原发性高血压病602例中医证候流行病学研究[J].浙江中西医结合杂志,2003,13(4)：261.
[125]仲昱,王钢,倪斌.高血.压肾损害内风伤肾证候学研究[J].甘肃中医,2007,20(8)：24-25
[126]冯国标.中西医结合治疗肾性高血压96例观察[J].实用中医药杂志,2001,17
[127]杨帆,戴小华,王建彬.原发性高血压早期肾损害中医证候学观察[J].安徽中医学院学报.2007,26(2),8-11
[128]程十德.内经[M].北京：人民出版社,1987,第1版：55
[129]唐洪波.女贞子善治冠心病及眩晕症[J].中华养生保健,2004;(8)：43
[130]尚伟芬,于澎仁.天麻药理作用研究进展[J].中草药,1997,25(10)：629-630.
[131]林泽鹏,徐明星,方卫华,原发性高血压患者血清脂联素浓度的变化及肾素一血.管紧张素系统对其影响[J],中国循环杂志,2004,19(3)：205-207
[132]Yoshio I, Tomohiro K, Kazuhikol, et al. Hypoadiponectinemiais an independent risk factor for hypertension[J]. Hypertension,2004,43:1318-1323.
[133]lwashima Y, Katsuya T, Ishiawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension[J]. Hypertension,2004; 43:1318-23.
[134]周淑娴,雷娟,张玉玲,等,高血压患者胰岛素抵抗与血.清脂联素及炎症标志物水平[J],中华高血.压杂志.2008,16(2)：166-170
[135]李嘉强,戴颖秀,刘玉敏,等.高血压患者血清脂联素与游离脂肪酸、糖及脂代谢[J].高血压杂志,2006,14.352—355.
[l36]Wang Y, Lam KS, XuJY, et al. Adiponectin inhibits cellproliferation by interacting with several growth factors in anoligomerization-dependent manner[J]. J Biol Chem,2005, 280 (18):18341-18347.
[137]Danesh J, Wheeler JG, Hirschfield GM, et al. Oreactive proteinand other circulating markers of inflammation in the prediction ofcoronary heart disease [J]. N Engl J Med 2004:350:1387-1397.
[138]Pearson TA, Mensah GA, Alexander RW, et al. Markers ofinflammation and cardiovascular disease:application to clinical andpublic health practice:a statement for healthcare professionals from theCenters for Disease Control and Prevention and the American HeartAssociation[J]. Circulation 2003:107:499-511.
[139]Libby P, Willerson JT, Braunwald E. C-reactive protein and coronary heart disease. N Engl J Med 2004:351:295-296.
[140]崔倩卫,冷吉燕,卜丽梅,高血压伴胰岛素抵抗患者血清脂联素水平与动脉粥样硬化的相关性研究[J],中国老年医学杂志2011,6(31)：1959-1960
[141]Tsioufis C, Dimitradis K, Selima M, et al. Low—grade inflamma—tion and hypoadiponectinaemia have an additive detrimental effecton aortic stiffness in essential hypertensive patientsr[J]. Eur HeartJ,2007,28:1162 1169.
[142]Fantuzzi G. Adipose tissue, adipokines, and inflammation [J]. JAllergy Clin Immunol, 2005,115:911-920.